St. Jude Medical (STJ) Stock Lower Ahead of Q2 Results

St. Jude Medical (STJ) stock is declining Tuesday afternoon ahead of the medical device company’s 2016 second quarter earnings due out before tomorrow’s opening bell.
By Kaya Yurieff ,

NEW YORK (TheStreet) -- Shares of St. Jude Medical (STJ) are down 0.65% to $80.04 Tuesday afternoon ahead of the company's 2016 second quarter results due out before tomorrow's market open.

Analysts are modeling an increase year-over-year in earnings and revenue.

Wall Street is expecting the Saint Paul, MN-based medical device maker to post earnings of $1.06 per share on revenue of $1.55 billion.

During the same quarter last year, St. Jude reported adjusted earnings of $1.03 per share on revenue of $1.41 billion.

Earlier this year, the company agreed to be acquired by Abbott Laboratories (ABT). Abbott is also scheduled to report its 2016 second quarter earnings before tomorrow's opening bell.

Separately, TheStreet Ratings Team has a "Buy" rating with a score of B on St. Jude stock.

The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, expanding profit margins and notable return on equity.

The team believes its strengths outweigh the fact that the company has had sub par growth in net income.

Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

You can view the full analysis from the report here: STJ

Loading ...